SCHEMBL26229267

SCHEMBL26229267

CC(C)C(=O)CCCCCc1ccc(Cl)c(OCS)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ ALOX5 P09917 1/20 0.38
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C8 P10632 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2B6 P20813 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ PPARG P37231 1/20 0.36
▸ PPARA Q07869 1/20 0.36
▸ FFAR1 O14842 2/20 0.36
▸ FFAR4 Q5NUL3 2/20 0.36
▸ PYGL P06737 1/20 0.35
▸ S1PR1 P21453 1/20 0.35
▸ HPGD P15428 1/20 0.34
▸ NLRP1 Q9C000 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ CDK8 P49336 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23842320 0.89 PPARG (0.40) MEN1KMT2AALOX5CYP1A2CYP3A4
SCHEMBL26203896 0.88 PTGER1 (0.39) MEN1KMT2AALOX5PPARGPPARA
SCHEMBL25123141 0.83 PPARG (0.38) MEN1KMT2ACYP1A2CYP3A4CYP2C8
SCHEMBL22525838 0.77 TSHR (0.39) MEN1KMT2AALOX5CYP1A2CYP3A4
SCHEMBL26224287 0.76 PPARA (0.49) PPARGPPARA
SCHEMBL25122669 0.75 BCHE (0.41) MEN1KMT2AALOX5CYP1A2CYP3A4
SCHEMBL26224307 0.75 LTB4R (0.37) ALOX5PPARGPPARA
SCHEMBL29307148 0.75 TSHR (0.37) MEN1KMT2AALOX5CYP1A2CYP3A4
SCHEMBL23842319 0.74 KEAP1 (0.42) ALOX5CYP1A2CYP3A4CYP2C8CYP2C9
SCHEMBL25122727 0.74 PPARG (0.40) CYP1A2CYP3A4CYP2C8CYP2C9CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746120-B2 Stat degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-09-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11746120-B2 Stat degraders and uses thereof STAT4, STAT1, STAT3 MEN1 3280/4885KMT2A 737/4885ALOX5 1655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback